The c-MET (mesenchymalepithelial transition factor) pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination. The c-MET receptor tyrosine kinase can be activated via gene mutation, gene amplification, protein overexpression and/or a ligand-dependent autocrine/paracrine loop. Abnormalities in c-MET signaling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Significant progress has been made in advancement of c-MET pathway inhibitors through to clinical trials. A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being explored in phase I, II and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity with these agents, along with an acceptable toxicity profile. In this manuscript, the pharmacological profile of drugs targeting the c-MET pathway and available data from ongoing clinical trials of these drugs are discussed.
Introduction
Inhibiting c-MET (mesenchymalepithelial transition factor) signaling is emerging as a promising strategy for a new class of targeted cancer therapies. Several c-MET inhibitors are in various stages of clinical development and have demonstrated activity in different tumor types. c-MET is a receptor tyrosine kinase encoded by the proto-oncogene MET and has a high affinity for hepatocyte growth factor (HGF; also known as scatter factor, SF) [Cooper et al. 1984] . Activation of c-MET, mediated by HGF binding, promotes several processes involved in oncogenesis, including tumor cell proliferation, migration, invasion, angiogenesis, protection from apoptosis and metastasis, working through several other signaling pathways such as PI3K/Akt, Src, STAT3, and Ras/Mek [Comoglio et al. 2008; Zhang et al. 2003; Trusolino and Comoglio, 2002; Furge et al. 2000 ].
The c-MET pathway is frequently dysregulated in human cancers, and aberrant c-MET signaling has been reported in a wide variety of human malignancies, including gastric, lung, colon, breast, bladder, head and neck, ovarian, prostate, thyroid and pancreatic as well as hematologic malignancies and central nervous system tumors [Liu et al. 2008; Birchmeier et al. 2003; Di Renzo et al. 2000; Ferracini et al. 1995] . Oncogenic activation of c-MET signaling can be induced by specific genetic lesions, transcriptional upregulation, ligand-dependent autocrine or paracrine mechanisms [Bean et al. 2007; Schmidt et al. 1997; Houldsworth et al. 1990 ]. Inherited and somatic mutations in MET have been found in papillary renal carcinoma tumor samples, providing strong direct evidence of the pathway's oncogenic potential [Jeffers et al. 1997; Schmidt et al. 1997 ]. In addition, there is accumulating evidence that acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and angiogenesis inhibitors can be due, in part, to increased activation of the c-MET pathway [Ebos et al. 2009; Engelman et al. 2007 ]. For example, amplification of MET leads to gefitinib resistance in lung cancer by mediating HER3-dependent activation of PI3 kinase and these tumors are sensitive to c-MET inhibitors [Bean et al. 2007; Engelman et al. 2007] .
Approaches to inhibiting the c-MET axis in the clinic Several strategies have been developed to inhibit the c-MET signaling pathway in cancer, each focusing on one of the serial steps that regulate MET activation (Figure 1 ). These strategies include selective c-MET kinase inhibitors such as tivantinib (ARQ 197) , JNJ-38877605 and PF04217903 which have specific selectivity for c-MET receptor tyrosine kinases; nonselective c-MET kinase inhibitors such as PF02341066, cabozantinib (XL184), GSK1363089, MK-2461, MP470 and MGCD265 which have broad activity against c-MET and other receptor tyrosine kinases; anti-c-MET monoclonal antibodies (MetMAb) are also selective, but bind to the receptor, leading to internalization and degradation as opposed to inhibiting tyrosine kinase activity; anti-HGF monoclonal antibodies (AMG102, SCH900105) bind to the circulating ligand, HGF; and c-MET/HGF competitors (NK4).
In this review, an overview of c-MET pathway inhibitors will be provided, supported by available phase II clinical trial data.
Tivantinib

Pharmacological profile
Tivantinib (ARQ 197) is an oral, highly selective, non-adenosine triphosphate (ATP)-competitive c-MET inhibitor, which is now in phase III development. In a panel of 230 human protein kinases, tivantinib only selectively inhibited c-MET to an appreciable extent; this high degree of selectivity is related to its ability to decrease V max (The maximum activity) without affecting the K m (Michaelis constant) of ATP and suggests a non-ATP-competitive mechanism of inhibition [Munshi et al. 2010; Jeay et al. 2007 ]. Tivantinib . Schematic representation of the c-MET (mesenchymalepithelial transition factor) dependent signaling pathway. Activation of c-MET results in the recruitment of several SH2-domain-containing signal transducers that in turn activate a number of pathways, including the GRB2SOSRASRAFMEKERK axis, leading to cell proliferation and invasion [Furge et al. 2000 ]. Strategies to inhibit c-MET signaling have therefore targeted different steps involved in c-MET activation. Ab, antibody; HGF, hepatocyte growth factor.
activity has been assessed against c-MET in different cancer cell lines and xenograft tumor models [Gu et al. 2009] , and inhibits c-MET phosphorylation and downstream signaling in different human cancer cell lines with a 50% inhibitory concentration (IC 50 ) of 100300 nM [Munshi et al. 2010 ]. The antiproliferative effect of tivantinib is related to c-MET signaling, as in c-MET null human cancer cell lines, little, if any antiproliferative effect was observed [Munshi et al. 2010] . Tivantinib inhibits c-MET receptor kinase within 24 h of administration and can be sustained for up to 812 h following withdrawal of tivantinib [Gu et al. 2009 ].
Treatment of different tumor xenograft-bearing mice with tivantinib has demonstrated significant tumor growth reductions of 4579% in colon, gastric, breast, prostate and pancreatic cancer models [Munshi et al. 2010; Anderson et al. 2007; Li et al. 2007 ]. In human colon xenograft tumors, a significant reduction in c-MET autophosphorylation was observed within 24 h following single oral dose administration of tivantinib, and plasma levels of tivantinib were more than threefold above the tivantinib K i (inhibitory constant) for c-MET at 10 h [Munshi et al. 2010] . Consistent with the role of c-MET signaling in metastasis, tivantinib has also demonstrated the ability to prevent bone metastases in mouse models of metastatic breast cancer and colon cancer [Anderson et al. 2007; Li et al. 2007 ].
Clinical development
Among c-MET inhibitors, tivantinib is the most advanced in clinical development. Several phase I and phase II studies have been completed and phase III trials are in process [Adjei et al. 2011a] .
Phase I dose-escalation study of tivantinib in advanced solid tumors
Data from an open-label, single-center, phase I study of tivantinib in advanced solid tumors were recently reported [Yap et al. 2011] . Tivantinib was administered orally at 100400 mg twice daily continuously in 28-day cycles. Fifty-one patients with advanced solid tumors were enrolled into sequential dose-escalation cohorts. The most common toxicities were grade 12 fatigue (n ¼ 8; 15.7%), nausea (n ¼ 7; 13.7%) and vomiting (n ¼ 6; 11.8%). In the 400 mg twice daily cohort, a dose-limiting toxicity (DLT) of grade 3 febrile neutropenia was observed in two patients. In one of these patients, two other grade 3 DLTs (mucosal inflammation and palmarplantar erythrodysesthesia) were also observed. All DLTs resolved within 2 weeks of tivantinib discontinuation. Data from this study recommended the use of tivantinib 360 mg twice daily in phase II studies. Mean time to maximum plasma concentration and half life for tivantinib were 2 and 5 h, respectively, and systemic exposure to tivantinib [maximum plasma concentration and area under the curve (AUC)] increased with increasing dose. Steady-state cumulative mean trough plasma concentration achieved for all dose levels of tivantinib was at 661 ng/ml (day 29 of treatment), which was well above the IC 50 for in vitro c-MET inhibition of 0.3 mmol/liter (110 ng/ml). Tivantinib decreased intratumoral phosphorylated c-MET, total c-MET, phosphorylated focal adhesion kinase and increased apoptosis as shown by TUNEL assays. More than three circulating tumor cells at baseline were detected in 15 patients, eight (53.3%) of whom had more than a 30% decline in circulating tumor cells after treatment. A decline of up to 100% in circulating endothelial cell counts after treatment was observed in 25 (58.1%) patients [Yap et al. 2011; Adjei et al. 2011a] . No significant change in dynamic contrast-enhanced magnetic resonance imaging parameters were observed after 7 days of tivantinib treatment. The best treatment response in this phase I trial was stable disease (SD) for over 4 months in 14 patients (27%), with minor regressions in gastric and Merkel cell carcinomas. One patient with metastatic melanoma with T276A MET mutation experienced SD for 20 weeks and had a marked improvement in symptoms.
Phase I dose-escalation study of tivantinib in combination with sorafenib in advanced solid tumors This study was undertaken based on the preclinical synergy of tivantinib in combination with sorafenib. The primary objective of the study was to define the maximum tolerated dose and recommended phase II dose of tivantinib in combination with sorafenib. The preliminary results were presented at the 2011 Annual Meeting of the American Society of Clinical Oncology [Adjei et al. 2011b] . Twenty-two patients were enrolled and treated at two dose levels. No DLTs were observed at the first dose level of tivantinib 360 mg twice daily plus sorafenib 200 mg twice daily. For the next cohort, dosing was increased to the full single-agent dose of both drugs: tivantinib 360 mg twice daily plus sorafenib 400 mg twice daily. One of nine patients (11.1%) at dose level 2 experienced two DLTs (grade 3 fatigue and grade 3 dyspnea), making this dose level the recommended phase II dose. The most commonly reported drug-related adverse effects of any grade were fatigue (36.4%), diarrhea (27.3%), anorexia (22.7%) and rash (22.7%). Pharmacokinetic analysis indicated that sorafenib had no effect on the disposition of tivantinib.
Among 14 of 18 patients with evaluable responses, a best response of SD for 732 weeks (median 12 weeks) was demonstrated [Adjei et al. 2011b] . The majority of patients with SD had renal cell cancer or hepatocellular cancer. These results indicate that a combination of sorafenib and tivantinib is safe and may have therapeutic potential.
Phase I dose-escalation study of tivantinib in combination with gemcitabine in advanced solid tumors This ongoing multicenter, phase Ib dose-escalation trial is examining the safety and tolerability of tivantinib at doses of 120360 mg twice daily across different schedules (continuous versus continuous with 1 week break every 2 or 3 weeks) in combination with gemcitabine at 1000 mg/m 2 / weekly Â 3 every 4 weeks [Camacho et al. 2011 ].
As of January 2011, a total of 32 patients with metastatic breast (12), ovarian (14), and uterine (6) carcinoma were enrolled and treated. No DLTs were observed. The most commonly observed adverse effects were thrombocytopenia (66%), anemia (66%), neutropenia (63%), fatigue (34%), nausea (31%), and leukopenia (13%). Treatment-related serious adverse effects were observed in three patients (pancytopenia, thrombocytopenia, hypotension and interstitial lung disease, grade 3) [Camacho et al. 2011 ]. Among the 27 patients with evaluable responses, five (two breast, one uterine, two ovarian) had partial response (PR, response rate 19%), and 15 had decline (487%) in tumor markers (CA15.3, CA125, CEA). Two patients (with ovarian and breast carcinoma) with PR and two with SD (with breast carcinoma) had failed to respond to prior gemcitabine. On the basis of the favorable safety profile and encouraging signs of antitumor activity, phase II combination studies are being planned in different tumor types.
Randomized, placebo-controlled phase I/II study of tivantinib, irinotecan and cetuximab in patients with wild-type KRAS metastatic colorectal cancer who received front-line systemic therapy This study is based on the hypothesis that adding tivantinib to irinotecan plus cetuximab may decrease resistance to cetuximab treatment and improve patient outcomes. Patients with locally advanced or metastatic colorectal cancer who received more than one prior line of chemotherapy, were KRAS wild type and had Eastern Cooperative Oncology Group performance status less than 2 were included in this study [Bessudo et al. 2011] . Patients were treated with irinotecan (180 mg/m 2 ) and cetuximab (500 mg/m 2 ) every 2 weeks along with escalating doses of tivantinib (120, 240, 360 mg) twice daily. Preliminary toxicity and efficacy data are available for nine patients. No DLTs were observed and grade 3/4 adverse events included neutropenia (grade 4 in one patient), fatigue (grade 3 in two patients) and one case each of grade 3 leukopenia, acneiform rash, vomiting, diarrhea, anemia and syncope. In nine patients with evaluable responses, best responses included one complete response (CR) (after four cycles), 2 PRs (after two cycles), five SD and one progressive disease [Bessudo et al. 2011 ]. The randomized phase II portion of the study continues to accrue data for the recommended phase II dose of 360 mg tivantinib twice daily.
Phase II combination study of tivantinib plus erlotinib versus erlotinib plus placebo in metastatic non-small cell lung cancer A multicenter, randomized, placebo-controlled, double-blind phase II study designed to compare treatment with tivantinib plus erlotinib with erlotinib plus placebo in patients with inoperable, locally advanced/metastatic non-small cell lung cancer (NSCLC) was recently completed ( Figure 2) [Schiller et al. 2010 ]. This study enrolled patients who had received one prior chemotherapy regimen (other than an EGFR inhibitor) for NSCLC. Eligibility criteria included confirmed availability of archival tissue suitable for analysis of KRAS, EGFR, and c-MET. Eligible patients (n ¼ 167) were randomly assigned to receive either erlotinib 150 mg once daily plus tivantinib 360 mg twice daily (n ¼ 84) or erlotinib 150 mg once daily plus placebo twice daily (n ¼ 83) in a 28-day cycle [Schiller et al. 2010 ].
Progression-free survival (PFS) was prolonged with the combined treatment of erlotinib plus tivantinib compared with erlotinib plus placebo (16.1 versus 9.7 weeks) among intention-to-treat patients [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.571.15, p ¼ 0.23) ( Table 1) . Multivariate analysis adjusting for prognostic factors (histology, genotype) resulted in PFS HR 0.68 (95% CI 0.470.98; p < 0.05). This improvement in PFS was paralleled by a similar improvement in median overall survival (36.6 versus 29.4 weeks). Patients with nonsquamous histology benefited most, with a 9.2-week improvement in median PFS (18.9 versus 9.7 weeks) and a 13.7-week improvement in median overall survival (43.1 versus 29.4 weeks). Subgroup analyses showed benefits of the tivantinib plus erlotinib combination in patients with MET fluorescent in situ hybridization (FISH) gene copy number greater than 4, EGFR wild-type status, and KRAS mutation status.
Of patients with an evaluable response, PRs were observed in seven of 73 (10%) in the tivantinib plus erlotinib arm compared with five of 72 (7%) in the erlotinib plus placebo arm. Disease control rates were 66% and 54% respectively (Table 1 ) [Schiller et al. 2010 ].
Interestingly, this study also demonstrated the potential antimetastatic activity of tivantinib.
For intention-to-treat patients, median time to new metastatic lesions was increased from 3.6 months in the erlotinib plus placebo arm to 7.3 months in the tivantinib plus erlotinib arm (HR 0.49; 95% CI 0.310.78). Patients with nonsquamous histology had an even more pronounced effect, with median time to metastatic disease being increased from 3.6 to 11.0 months (HR 0.46; 95% CI 0.260.82) (Table 1) [Sequist et al. 2010] .Overall, treatment with tivantinib was well tolerated with no significant differences in adverse effects between treatment and control arms. The most frequent adverse effects included grade 1/2 rash, diarrhea, anorexia, anemia and fatigue [Schiller et al. 2010 ]. Based on the results of this study, a global phase III randomized, double-blind, placebo-controlled study of tivantinib plus erlotinib in previously treated patients with metastatic nonsquamous NSCLC is currently ongoing (Table 4) .
MetMAb
Pharmacological profile
MetMAb is a monovalent monoclonal antibody directed against c-MET, which prevents HGF Therapeutic Advances in Medical Oncology 3 (1) 
Tivantinib (ARQ 197)
A phase 1 dose escalation study of ARQ 197 given twice daily continuously in adult patients with advanced solid tumors A randomized, placebo-controlled, phase 1/2 study of ARQ 197 in combination with irinotecan and cetuximab in subjects with metastatic colorectal cancer with wild-type KRASs who have received front-line systemic therapy A phase 2 randomized open-label study of erlotinib plus ARQ 197 versus single agent chemotherapy in previously treated KRAS mutation positive subjects with locally advanced or metastatic non-small cell lung cancer A phase 2 randomized open-label study of erlotinib plus ARQ 197 versus single agent chemotherapy in previously treated KRAS mutation positive subjects with locally advanced or metastatic non-small cell lung cancer A phase 1 dose escalation study of ARQ 197 administered in combination with gemcitabine in adult patients with advanced solid tumors A randomized controlled phase 2 trial of ARQ 197 in patients with unresectable hepatocellular carcinoma (HCC) who have failed one prior systemic therapy A phase 1 dose escalation study of ARQ 197 in combination with sorafenib in adult patients with advanced solid tumors A phase 3, randomized, double-blind, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC) A randomized phase 2 study of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with locally advanced or metastatic gastric cancer who have progressive neoplastic disease following treatment with one prior chemotherapy regimen A phase 1b safety study of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC) A randomized phase 2 study of ARQ 197 versus gemcitabine in treatment-naïve patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma A study of ARQ 197 in healthy volunteers to assess the pharmacokinetic (PK) profile in extensive and poor metabolizers as defined by cytochrome P450 2C19 (CYP 2C19) genotype A phase 3, randomized, double-blinded, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small-cell lung cancer with wild-type epidermal growth factor receptor A phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated tumors Multicenter phase 2 trial of ARQ 197 for subjects with relapsed or refractory germ cell tumors An open-label, phase 1, randomized, two-treatment, two-period, two-way crossover, relative bioavailability study of a capsule and a tablet formulation of ARQ 197 in subjects with advanced solid tumors Phase II study of ARQ 197 monotherapy for previously treated advanced/recurrent gastric cancer A phase I study of ARQ 197 in combination with erlotinib in CYP2C19 poor metabolizer patients with advanced/recurrent nonsmall-cell lung cancer XL184 (cabozantinib) A randomized discontinuation study of XL184 in subjects with advanced solid tumors A phase 1 dose finding study of the safety and pharmacokinetics of XL184 administered orally in combination with temozolomide and radiation therapy in the first line treatment of subjects with glioblastoma A phase 1b/2 study of XL184 with or without erlotinib in subjects with non-small cell lung cancer An international, randomized, double-blinded, phase 3 efficacy study of XL184 versus placebo in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer A phase 1 dose-escalation study of the safety and pharmacokinetics of XL184 administered orally to subjects with advanced malignancies A phase 1 drugdrug interaction study of the effects of XL184 on the pharmacokinetics of a single oral dose of rosiglitazone in subjects with solid tumors A phase 2 study of XL184 in subjects with progressive or recurrent glioblastoma multiforme in first or second relapse A phase 2 non-comparative randomized open-label study of multiple regimens of single-agent XL184 in subjects with grade IV astrocytic tumors in first or second relapse Dose-finding pilot study of XL184 in men with castrate-resistant prostate cancer and bone metastases Foretinib A phase 2 study of the MET RTK inhibitor foretinib in subjects with recurrent or metastatic squamous cell cancer of the head and neck A phase 2 study of the MET RTK inhibitor foretinib in subjects with recurrent or metastatic squamous cell cancer of the head and neck An open-label, randomized, two-way balanced crossover study to investigate the bioavailability of two forms of foretinib in subjects with solid tumors A phase 1/2, open-label, multicenter study of foretinib in adult subjects with hepatocellular carcinoma A phase 2 study of the c-MET RTK inhibitor foretinib in subjects with papillary renal-cell carcinoma A phase 2 study of foretinib administered orally to subjects with metastatic gastric cancer a phase 1 dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to subjects with solid tumors A phase I/II study of foretinib in combination with lapatinib in patients with human epidermal growth factor receptor 2 (HER2) overexpressing metastatic breast cancer (continued) N Sharma and AA Adjei from binding to the c-MET receptor, thereby blocking HGF-induced dimerization and receptor activation. Attempts to inhibit c-MET signaling using monoclonal antibodies have been challenging because most antibodies have intrinsic agonistic activity and single antibodies have been unable to completely block the SF/HGF:c-MET binding [Cao et al. 2001; Ohashi et al. 2000; Prat et al. 1998 ]. Recently, a one-armed variant of the anti-c-MET antibody 5D5, MetMAb, was developed to avoid agonistic activity that can occur when divalent antibodies bind and crosslink MET receptors. MetMAb binds to the Sema domain of c-MET, a region which is critical for binding HGF [Nguyen et al. 2003 ].
MetMAb inhibited c-MET tyrosine phosphorylation, cell proliferation, migration, and apoptosis in U87 glioblastoma cells, strongly driven by autocrine or paracrine SF/HGF-c-MET signaling [Martens et al. 2006 ]. Treatment of the orthotopic model of U87 and G55 tumors with MetMAb significantly inhibited growth only in SF/HGF-activated tumors. In addition, in MetMAb-treated tumors, cell proliferation was reduced more than 75%, microvessel density was reduced more than 90% and apoptosis was increased more than 60%. In a c-MET-and HGF-expressing, autocrine-driven, human KP4 pancreatic cancer orthotopic model, MetMAb also significantly inhibited c-MET phosphorylation, with a concomitant decrease in tumor growth and improvement in survival [Jin et al. 2008] .
Phase I study of MetMAb in combination with bevacizumab in patients with advanced solid malignancies
The combination of MetMAb with bevacizumab was tested in a phase I study which consisted of three parts: 3 þ 3 dose escalation of MetMAb evaluating 1, 4, 10, 15, 20, and 30 mg/kg intravenously every 3 weeks; expansion at 15 mg/kg intravenously every 3 weeks; and combination of MetMAb at 10 and 15 mg/kg plus bevacizumab 15 mg/kg intravenously every 3 weeks. Baseline and post-treatment serum was collected for evaluation of pharmacodynamic biomarkers possibly affected by inhibition of c-MET and/or vascular endothelial growth factor (VEGF) signaling [Moss et al. 2010 [Moss et al. , 2011 .
A total of 43 patients (21 in escalation, 13 in expansion, nine in combination) were treated [Moss et al. 2010 [Moss et al. , 2011 . The most frequently observed toxicities were fatigue, peripheral edema and hypoalbuminemia. No grade 35 treatment-related adverse events were reported with the combination; a grade 1 and DLT of hemoptysis was reported in one patient with central necrosis of pulmonary metastases. There were no pharmacokinetic interactions with bevacizumab, and MetMAb had a half life of 11 days. CR was observed in one patient with gastric carcinoma after four cycles of single-agent MetMAb. The combination of MetMAb with bevacizumab was safe and well tolerated. A phase II trial of MetMAb in combination with bevacizumab plus paclitaxel in patients with triple-negative breast cancer is currently ongoing (Table 4) .
Phase II study evaluating MetMAb in combination with erlotinib in patients with advanced NSCLC In a randomized, double-blind phase II study, MetMAb 15 mg/kg intravenously plus erlotinib was compared with erlotinib plus placebo in 128 patients with advanced NSCLC (Figure 3 ) [Spigel et al. 2011] . The study included patients with all histologies following at least one chemotherapy-containing regimen for stage IIIB/ A phase II study of foretinib in patients with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negative, recurrent/metastatic breast cancer A phase I/II study of foretinib in patients with previously treated non-small cell lung cancer receiving standard erlotinib therapy MetMAb A phase I, open label, dose escalation study of the safety and pharmacology of MetMAb (PRO143966), a monovalent antagonist antibody to the receptor c-MET, administered intravenously in patients with locally advanced or metastatic solid tumors A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of MetMAb in combination with paclitaxel and bevacizumab in patients with metastatic, triple-negative breast cancer A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and activity of MetMAb, a monovalent antagonist antibody to the receptor MET, administered to patients with advanced non-small cell lung cancer, in combination with Tarceva (erlotinib) IV disease. Patients in the control arm had the option of being unblinded and crossing over to receive MetMAb after disease progression. Immunohistochemistry (IHC) was performed for c-MET in 121 patients. Those patients whose tumors stained 2þ or 3þ were defined as 'MET high', whereas those with either no expression or 1þ expression were defined as 'MET low'. Archival tissue was evaluable for EGFR and KRAS mutations in 112 patients. Both treatment groups were well balanced with respect to molecular genotype and 54% of patients were c-MET-positive, which was associated with a poorer outcome (overall survival HR 2.52, placebo plus erlotinib cohort).
In patients with high c-MET, the combination of MetMAb plus erlotinib resulted in a significant improvement in both PFS and overall survival, resulting in a near threefold decrease in the risk of death. In a predefined population with c-MET overexpression (c-MET IHCþ), PFS in the MetMAb plus erlotinib combination group was approximately 3 months compared with 1.5 months in the erlotinib plus placebo group (HR 0.47; 95% CI 0.260.85; p ¼ 0.01). A trend for overall survival benefit (HR 0.37; 95% CI 0.200.71; p ¼ 0.002) in these patients was also seen with MetMAb plus erlotinib. The overall survival benefit was not exclusive to EGFR mutation or MET FISHþ but was also observed in patients who were FISH/IHCþ, suggesting that IHC may be a more sensitive predictor of benefit from MetMAb (Table 2) . Of note, the removal of patients with EGFR mutation did not appear to affect these results.
Foretinib
Pharmacologic profile Foretinib (formerly XL880) is an oral multikinase inhibitor developed to target c-MET and several other receptor tyrosine kinases involved in tumor angiogenesis. It has a nanomolar IC 50 for in vitro and in vivo inhibition of c-MET and VEGF receptor-2 (VEGFR-2), together with high in vitro affinity for platelet-derived growth factor receptor-b, Tie-2, RON, Kit, and FLT3 kinases [Qian et al. 2009 ]. Foretinib is an ATPcompetitive inhibitor and binds deeply in the ATP pocket of both c-MET and VEGFR-2 tyrosine kinase domains with high affinity. In xenograft models of human cancers, treatment with foretinib caused necrosis and hemorrhage within 24 h of treatment and maximum tumor response (CR) was achieved at 96 h following five daily doses. Peak plasma concentrations after a single daily oral dose were 13 mmol/liter [Qian et al. 2009 ].
Phase I study of foretinib in patients with advanced solid tumors In a phase I, nonrandomized, dose-finding study, patients with metastatic or unresectable solid tumors refractory to standard chemotherapy received foretinib for 5 consecutive days, every 14 days [Eder et al. 2010] . Most frequently reported treatment-related adverse events were grade 1/2 hypertension, proteinuria and fatigue. Elevation in aspartate transaminase (AST) occurred in 10 patients (25%), with one grade 3 event. Three patients had study drug discontinuation due to treatment-related adverse events, which included grade 3 elevated lipase, grade 3 tumor hemorrhage and grade 4 hemorrhage into central nervous system metastasis. At the maximum tolerated dose (3.6 mg/kg), mean C max and AUC 0-24 values were 90.5 ng/ml (0.14 mmol/l) and 1300 ZgÁh/ml (2.05 mmol/lÁh) on day 1. On day 8, mean C max and AUC 0-24 increased to 218 Zg/ml (0.34 mmol/l) and 4050 ZgÁh/ml (6.40 mmol/lÁh after the administration of five consecutive daily doses). The median half life across all cohorts was approximately 40 h and T max was approximately 4 h on both days 1 and 8.
Three patients with melanoma, medullary thyroid cancer and triple-negative breast cancer had tumor biopsies for pharmacodynamic assessment of target inhibition and downstream pathway modulation. Total c-MET and total RON were unchanged; however phosphorylated c-MET and RON were reduced in the tumors of all three patients. A decrease in downstream signaling of pERK and pAkt was also observed, together with a marked decrease in proliferation and am increase in apoptosis, measured by Ki67 and TUNEL staining of tumor cells [Eder et al. 2010] .
Confirmed PRs were seen in two patients with papillary renal carcinoma and one patient with medullary thyroid carcinoma. Both patients with papillary renal carcinoma who had received no prior systemic therapy had a PR of more than 48 and 12 months, respectively. SD was observed in 22 patients (55%) [Eder et al. 2010] .
Cabozantinib
Pharmacologic profile Cabozantinib (XL184) is an oral, potent tyrosine kinase inhibitor that blocks c-MET, VEGFR2, AXL. KIT, TIE2, FLT3, and RET signaling. In the RIP-Tag2 transgenic mouse model of pancreatic neuroendocrine carcinoma, selective inhibition of VEGF reduced tumor growth but increased invasion, whereas treatment with cabozantinib decreased tumor growth, invasion, and metastasis leading to increased survival [Sennino et al. 2009 ].
Phase I study of cabozantinib in patients with advanced malignancies Cabozantinib was administered on two different schedules of days 15 (5 and 9 schedule) or continuously on a daily basis [Salgia et al. 2008] . Fifty-five patients were treated at 13 different dose levels. DLTs included one report each of grade 3 palmar/plantar erythema, grade 3 AST, alanine aminotransferase and lipase elevations, as well as grade 2 and 3 mucositis. Other frequent treatment-related adverse events were diarrhea and hypopigmentation of the hair. Data suggested linear pharmacokinetics with a terminal half life of 59136 h. Three patients with medullary thyroid cancer and one patient with neuroendocrine carcinoma had a PR, while SD was observed in 20 patients, which lasted for more than 6 months in 12 of these patients. Pharmacodynamic assessment of plasma samples showed a trend towards increased VEGF-A, placenta growth factor, and reduced soluble VEGFR-2 levels.
Phase Ib/II study of cabozantinib with and without erlotinib in patients with NSCLC Fifty-four patients with NSCLC with previously treated advanced NSCLC received different combinations of cabozantinib and erlotinib in a 3 þ 3 design (75 mg cabozantinib plus 150 mg erlotinib, 50 mg cabozantinib plus 150 mg erlotinib, 75 mg cabozantinib plus 100 mg erlotinib, 125 mg cabozantinib plus 100 mg erlotinib, and 125 mg cabozantinib plus 50 mg erlotinib) [Wakelee et al. 2010] . Twelve patients experienced at least one DLT: diarrhea, elevated AST, palmar-plantar erythrodysesthesia, mucositis, hypertension, hypokalemia, elevated lipase, and fatigue. The most frequent adverse events were grade 3/4 diarrhea (26%), fatigue (15%), dyspnea (12%), and hypoxia (9%). No drug interaction was found in the preliminary pharmacokinetic analysis. Three patients with prior erlotinib treatment had a reduction of at least 30% in tumor measurements. One of these patients had c-MET amplification. Prolonged SD for at least 4 months was observed in some patients, including one patient with EGFR T790M mutation [Wakelee et al. 2010] .
Phase II randomized discontinuation trial of cabozantinib in advanced solid tumors A phase II study evaluated the activity of cabozantinib in patients with breast, gastric/gastroesophageal junction, small cell lung, non-small cell lung, ovarian, pancreatic, hepatocellular or prostate cancers, or melanoma [Schö ffski et al. 2010 ]. The study consisted of two stages: a lead-in stage (stage 1) and a double-blind randomized stage (stage 2) (Figure 4) . For the lead-in stage, all patients received 100 mg of cabozantinib daily for 12 weeks. At the end of stage 1, patients with CR/PR continued to receive the same dose of cabozantinib, patients with progressive disease discontinued treatment and those with SD were randomized 1:1 to receive cabozantinib in stage 2 until disease progression.
Patients randomized to placebo could cross over to cabozantinib upon progression. Efficacy endpoints were overall response rate at 12 weeks in stage 1 and PFS in stage 2, with early stopping rules in the lead-in stage to project futility.
Preliminary data from the lead-in phase of this study for individual tumor types are available (Table 3) [Yasenchak et al. 2010 ]. In the NSCLC cohort, a total of 36 patients were enrolled whose disease had failed to respond to up to three prior systemic treatments, and 20 patients had evaluable responses: two had a PR and eight achieved SD and were randomized. The overall disease control rate was 50% at 12 weeks and one patient with prior exposure to sunitinib achieved a 61% decrease in tumor growth at 12 weeks. Another patient previously treated with platinum-based chemotherapy and an EGFR inhibitor achieved a 32% reduction in tumor size. Diarrhea, fatigue, asthenia and pain in the extremities were the most frequently observed adverse events [Yasenchak et al. 2010 ].
In the melanoma cohort, 24 patients had evaluable responses: one patient achieved a PR and 11 patients achieved SD. The overall disease control rate was 50% at week 12 [Nechushtan et al. 2010] . A total of 12 patients with hepatocellular cancer and a ChildPugh score of A whose disease had failed to respond to up to one prior treatment regimen were enrolled: seven patients had evaluable responses and, of these, two patients achieved a PR and five patients achieved SD. The overall disease control rate was 88% at 12 weeks [Van Cutsem et al. 2010] . The preliminary results from a cohort of patients with castration-resistant prostate cancer were presented at the 2011 Annual Meeting of the American Society of Clinical Oncology [Hussain et al. 2011] . Accrual was halted at 168 and patients were unblinded due to high rates of observed clinical activity. Out of 100 patients with an evaluable response in the lead-in stage, 47% had visceral disease, 78% had bone metastasis, and 47% were docetaxel pretreated. The most frequent treatment-related grade 3/4 adverse events were fatigue (11%), hypertension (7%), and hand-foot syndrome (5%). Objective tumor shrinkage occurred in 84% of patients. The overall response rate at week 12 was 5%. Prostate-specific antigen changes were not related to clinical activity. The overall disease control rate (PR þ SD) at 12 weeks was 71%.
Patients with bone metastases (56 of 65, 86%) had either complete or partial resolution of lesions on bone scan as early as week 6. In 28 patients receiving narcotics for bone pain, 64% had improved pain and 46% decreased or discontinued narcotics. Measures of osteoclast and osteoblast activity, and plasma C-telopeptide declined at least 50% in 55% of patients and serum total alkaline phosphatase declined at least 50% in 56% of patients [Hussain et al. 2011 ].
In the ovarian cancer cohort, a total of 21 patients with epithelial ovarian cancer, primary peritoneal or fallopian tube cancer with measurable disease were enrolled. Out of seven patients with evaluable responses, three achieved an unconfirmed PR and four achieved SD. The most frequently observed adverse events were rash, palmar-plantar erythrodysesthesia syndrome, pruritus, pulmonary embolism and staphylococcal infection.
To date, 397 patients with different tumor types have been enrolled. Interim data for all tumor cohorts are summarized in Table 3 .
Conclusions
Preclinical studies strongly suggest abnormal c-MET signaling in many cancers, with data supporting targeting of this pathway for cancer intervention. There are various inhibitors in clinical development targeting different steps of c-MET activation. Many of these agents have demonstrated clinical activity in both phase I and II clinical trials and are being evaluated in several ongoing trials in a variety of tumor types (Table 4 ). Most studies have demonstrated favorable safety profiles for these agents, when used alone or in combination with other targeted agents. Of particular clinical interest, the data demonstrate activity of c-MET inhibitors in EGFR-resistant tumors and an increase in time to new metastasis. Inhibitors targeting multiple pathways, such as cabozantinib (VEGF, RET, and c-MET) may have more clinical activity across a wide spectrum of tumor types. Selective inhibitors may have activity in c-METdriven tumors. Combinations of these selective inhibitors and other agents such as EGFR tyrosine kinase inhibitors and VEGF inhibitors may be necessary for broader activity. The results of ongoing and planned clinical trials will shed more light on the tumor types that would benefit most from these agents, which biomarkers to use for prediction of clinical activity (c-MET amplification/overexpression/mutation) and which combinations of c-MET-inhibiting drugs with other agents are likely to be more effective.
